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Abstract  75 
Background & aims. The Modified Response Evaluation Criteria in Solid 76 
Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria 77 
in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate 78 
whether objective response by mRECIST accurately predicted overall survival (OS) in 79 
patients with advanced HCC treated with systemic targeted therapies and also to 80 
preliminarily assess this end-point as a potential surrogate of OS. 81 
Methods. Individual patient data from the BRISK-PS randomized phase III trial comparing 82 
brivanib vs. placebo (the first to prospectively incorporate mRECIST) were used to analyze 83 
objective response as a predictor of OS in a time-dependent covariate analysis. Patients 84 
with available imaging scans during follow-up were included (n = 334; 85% of those 85 
randomized). Moreover, a correlation of the survival probability in deciles vs. the observed 86 
objective response was performed to evaluate its suitability as a surrogate end-point. 87 
Results. Objective response was observed in 11.5% and 1.9% of patients treated with 88 
brivanib and placebo respectively, and was associated with a better survival (median OS 89 
15.0 vs. 9.4 months, p <0.001). In addition, objective response had an independent 90 
prognostic value (HR = 0.48; 95% confidence interval [CI], 0.26–0.91, p = 0.025) along with 91 
known prognostic factors. Finally, objective response showed promising results as a 92 
surrogate of OS in this trial (R = −0.92; 95% CI, −1 to −0.73, p <0.001). It was an early 93 
indicator of the treatment effect (median time to objective response was 1.4 months). 94 
Conclusions. Objective response by mRECIST in advanced HCC predicts OS and thus can 95 
be considered as a candidate surrogate end-point. Further studies are needed to support 96 
this finding. 97 
 98 
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Introduction 100 
In 60% of cases, patients with hepatocellular carcinoma (HCC) are diagnosed 101 
when tumors are no longer eligible for potentially curative therapies [1]. In this setting, only 102 
two treatments have been included in guidelines after demonstrating survival advantages in 103 
randomized controlled trials. Patients at an intermediate stage benefit 104 
from chemoembolization and have an estimated median overall survival (OS) of 105 
26 months [2], while at advanced stages, sorafenib extends survival from 8 to almost 106 
11 months [3]. 107 
The optimal management of HCC requires an early and accurate assessment of tumor 108 
response to therapy, particularly for those patients who experience toxicity [1]. Nevertheless, 109 
traditionally established response criteria based on size for tumor burden, as defined by 110 
World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid 111 
Tumors (RECIST), have been challenged in HCC due to the nature of effective treatments. 112 
Both chemoembolization and sorafenib often induce direct tumor necrosis without critically 113 
affecting tumor size [4]. Moreover, valid radiological criteria are crucial for the optimal 114 
development of clinical trials testing new therapies for HCC: although the primary goal is to 115 
prolong survival, alternative end-points evaluating disease response and progression have 116 
been used to assess treatment effectiveness earlier and reduce drug development costs [5]. 117 
In addition, controversy remains on what should be an ideal surrogate end-point in HCC 118 
research. Objective response was considered an adequate surrogate end-point when 119 
assessing benefits of loco-regional therapies [2,6] by European Society for the Study of the 120 
Liver (EASL) criteria [7]. These criteria were proposed in 2000 by a panel of experts as an 121 
amendment to WHO criteria, considering treatment-induced tumor necrosis and the concept 122 
of viable tumor assessment. However, the standardization of RECIST in trials evaluating 123 
oncologic therapies led to adopting these criteria for the first time in HCC in the SHARP 124 
trial [3]. This landmark trial demonstrated that sorafenib was able to significantly increase 125 
OS compared to placebo, despite an objective response rate (ORR) of just 2%. 126 
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Subsequently, experts convened by the American Association for the Study of Liver 127 
Diseases (AASLD) developed a set of guidelines that aimed to provide a common 128 
conceptual framework for the design of clinical trials in HCC and endorsed time to 129 
progression (TTP) as the optimal secondary end-point in 2008 [5]. At the same time, this 130 
provided the basis of the modification of RECIST criteria (mRECIST) [8]. These criteria 131 
incorporate the concept of viable tumor assessment, defined as the portions of tumor 132 
showing arterial enhancement, and thus providing improved sensitivity for clinical 133 
assessment. Moreover, mRECIST also incorporates novel concepts in assessing 134 
progression with lymph node involvement, ascites and development of 135 
new lesions [5,8] (Fig. 1). Thus, assessment of response by mRECIST was thereafter 136 
endorsed by the EASL clinical practice guidelines of management of HCC [1]. 137 
Several studies and one meta-analysis have shown a correlation between objective 138 
response by mRECIST and survival in patients treated with loco-regional therapies [9–13]. In 139 
advanced HCC cases treated with systemic targeted therapies, few studies suggest a 140 
prognostic value of objective response by mRECIST [14–17]. However, their retrospective 141 
nature and the absence of a time-dependent multivariate analysis considering immortal time 142 
bias, limit the level of evidence in this setting. 143 
We performed an individual patient data analysis of BRISK-PS, a phase III trial comparing 144 
brivanib and placebo in the second line setting that was the first to prospectively incorporate 145 
mRECIST for the assessment of treatment benefit [18]. The aim was to investigate whether 146 
objective response by mRECIST could accurately predict OS in patients with advanced HCC 147 
treated by systemic therapies. 148 
 149 
 150 
 151 
 152 
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Patients and Methods  153 
BRISK-PS Trial Design, Treatment and Assessments.  154 
BRISK-PS [18] was a multinational, double-blind, randomized, placebo-controlled, phase III 155 
study carried out between February 2009 and June 2011. Three hundred and ninety-five 156 
patients were randomly assigned (2:1) to receive brivanib, a dual inhibitor of vascular 157 
endothelial growth factor receptor and fibroblast growth factor receptor signaling pathways, 158 
800 mg once per day or matching placebo plus best supportive care (BSC). Patients were 159 
eligible if they had documented radiographic or symptomatic progression on/after or were 160 
intolerant to sorafenib. Patients were required to have one or more measurable target 161 
lesions. Other inclusion criteria included liver function of Child-Pugh Class A or B (a total 162 
score ⩽7) without ascites or encephalopathy an Eastern Cooperative Oncology 163 
Group performance status (ECOG PS) ⩽2, and adequate hematologic, hepatic and renal 164 
functions. Stratification was carried out according to reason for sorafenib discontinuation 165 
(progression vs. intolerance), ECOG PS score (0 vs. 1–2), distant metastasis and/or 166 
macrovascular invasion (yes vs. no) and study site. All patients provided written informed 167 
consent before enrollment. The study was approved by the institutional review board or 168 
ethics committee at each center and complied with provisions of the Good Clinical Practice 169 
guidelines and the Declaration of Helsinki and local laws. 170 
The primary end-point of OS was defined as the time from random assignmentuntil death as 171 
a result of any cause. Secondary end-points were TTP and ORR. TTP was defined as the 172 
time from random assignment to radiologic disease progression and ORR as the percentage 173 
of patients with complete response (CR) or partial response (PR). Tumor measurements 174 
were performed every 6 weeks during treatment by contrast-enhanced, computed 175 
tomography or magnetic resonance imaging. To define objective response, confirmatory 176 
assessments were performed ⩾28 days after the initial demonstration of the response. 177 
Assessment was performed by a blinded independent radiologic committee using mRECIST. 178 
Results of TTP and ORR were based on central review. Briefly, the study images were 179 
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subjected to quality control (adherence to image acquisition guidelines and trial protocol) 180 
before they were evaluated by two board-certified radiologists with specific expertise in liver 181 
imaging. If there was disagreement between the two reviewers in the response assessment 182 
at any time point, a third adjudicating radiologist reviewed the case and decided which of the 183 
two primary radiologists should be agreed with. In this regard, a previous study showed up 184 
to 73% of inter-reader agreement for mRECIST in HCC patients treated with sorafenib and a 185 
comparable weighted k coefficient to RECIST [15]. 186 
Overall, 226 of 263 brivanib patients (85.9%) and 108 of 132 placebo patients (81.8%) were 187 
evaluable for response because of the presence of baseline and at least one on-study scan. 188 
Of the 61 patients not evaluable due to discontinuation of treatment before the first 189 
radiological assessment, 27 survived less than 6 weeks. 190 
 191 
Statistical Analysis.  192 
Analyses were performed using the SPSS v.23 and SAS v.9.4 software packages. A 193 
Fisher’s exact test was used for comparison of frequency of two categorical variables. Mann-194 
Whitney U test compared one categorical variable with one continuous variable. The hazard 195 
ratio (HR) and their associated confidence interval (CI) for OS were computed by Cox 196 
proportional hazard models for the aforementioned stratification factors (reason for sorafenib 197 
discontinuation, ECOG PS score, distant metastasis and macrovascular invasion), region, 198 
age, sex, race, risk factors, baseline analytical factors (albumin, bilirubin and alpha-199 
fetoprotein [AFP]), nodal metastasis and objective response. Variables associated with OS 200 
(p value <0.10) in univariate analysis were included in multivariate models. Statistics 201 
involving evolutionary events were done by means of time-dependent covariate analysis. 202 
Survival curves were performed using Landmark Kaplan-Meier method without a fixed time 203 
(patients enter the objective response group as soon as they achieved this event); and were 204 
compared using the Mantel-Byar test; this method allowed analysis of survival from the point 205 
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where the variable changed [19,20]. The relationship between probability of survival in 206 
deciles and log (odds) (i.e., log [p/1 − p] where p is the prevalence of the end-point) for ORR 207 
was evaluated using Pearson’s correlation coefficient and linear regression; the 95% CI for 208 
the R were estimated by bootstrap with 10,000 simulations. The same approach was used to 209 
evaluate the association between log HRs for OS and log odds ratios for ORR after dividing 210 
the trial into five subgroups at random. All statistical tests were two-tailed and the threshold 211 
level of significance was 0.05. 212 
 213 
214 
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Results 215 
Objective response by mRECIST as an independent prognostic factor 216 
At the end of follow-up, 233 of the 334 patients with evaluable response had died, with a 217 
median OS of 10.1 months (95% CI; 8.6–11.6) and 9.5 (95% CI; 7.4–11.7) for brivanib and 218 
placebo groups respectively. There were no statistically significant differences between 219 
treatments (HR = 0.88; 95% CI, 0.67–1.16, p = 0.358), as observed in the whole BRISK-PS 220 
population (HR = 0.89; 95.8% CI, 0.69–1.15, p = 0.331). 221 
There was no CR in either of the two arms among patients evaluated. ORR was 11.5% 222 
(n = 26/226) with brivanib and 1.9% (n = 2/108) with placebo. Overall, considering all 223 
patients assessed, those patients achieving objective response (n = 28) had a median OS 224 
as per landmark analysis of 15.0 months (95% CI; 13.7–16.3), significantly better than the 225 
9.4 (95% CI; 8.2–10.6) months of patients without objective response (n = 306) (HR = 0.28; 226 
95%CI 0.14–0.54, p <0.001) (Fig. 2A). Specifically, for patients in the brivanib arm, those 227 
with objective response had better survival (14.3 vs. 9.4 months, HR = 0.31; 95%CI 0.16–228 
0.60, p <0.001) (Fig. 2B). 229 
In order to evaluate objective response as a predictor of OS we used a Cox model with 230 
objective response as a time-dependent variable, since this variable was measured after 231 
entry into the study. Multivariate analysis irrespective of treatment identified objective 232 
response by mRECIST as an independent prognostic factor of OS (HR = 0.48; 95% CI, 233 
0.26–0.91, p = 0.025) along with nodal metastasis, distant metastasis, macrovascular 234 
invasion, AFP >200 ng/ml, albumin > median and bilirubin > median (Table 1). Objective 235 
response maintained independent prognostic value in patients treated with brivanib 236 
(HR = 0.50; 95% CI, 0.25–099, p = 0.047) (Table 2), indicating that objective response by 237 
mRECIST captures those patients in which treatment changes the natural history of the 238 
disease. 239 
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Baseline demographics and disease characteristics that significantly influenced obtaining a 240 
higher percentage of objective response by mRECIST after treatment with brivanib were: 241 
BCLC A/B stage, absence of distant metastasis and the presence of low and high levels of 242 
AFP and albumin, respectively (Table 3). 243 
Objective response by mRECIST as a surrogate end-point 244 
To further explore the impact of objective response by mRECIST in the assessment of 245 
efficacy of a systemic molecular targeted therapy, we performed a Pearson correlation 246 
between the raw survival probability of patients in deciles and the log odds ratios of ORR. 247 
This method allowed the determination of the ORR observed in each one of the ten 248 
subgroups, sorted by worse to better outcome, and their association. As shown in Fig. 3, 249 
treatment effects on ORR and OS were significantly associated (R = −0.92; 95% CI, −1 to 250 
−0.73, p <0.001). 251 
In order to provide additional surrogacy of end-points, a proper correlation between the 252 
treatment effect on the surrogate outcome (objective response by mRECIST) and the 253 
treatment effect on the clinical outcome (OS) is required. To attempt this, we split the cases 254 
in five random subgroups of equal size (395/5 = 79). The association between log HRs for 255 
OS and log odds ratios for ORR was high (R = −0.80; 95% CI, −1 to 0.23, p = 0.091) (Fig. 256 
4). 257 
Of note, median time to objective response was 1.4 months (range: 0.7–8.4) in the 26 258 
patients that reached a PR with brivanib. This means that the first radiological evaluation, 259 
conducted at 6 weeks, detects the majority of patients responding to treatment and thus, 260 
objective response could be considered an early surrogate end-point.  261 
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Discussion 262 
OS remains as the main primary end-point in clinical research in oncology and in HCC. 263 
However, there is a need to identify a reliable secondary end-point able to recapitulate OS. 264 
This will allow ineffective drugs in phase II trials to be discarded, and enable testing new 265 
therapies in phase III, where median survivals of patients with intermediate HCC might 266 
exceed 30 months, and cross over treatments might dilute the potential benefits during 267 
follow-up. Objective response was previously considered a reliable surrogate end-point for 268 
loco-regional therapies in HCC [7], but studies assessing response by RECIST criteria failed 269 
to capture this benefit. At advanced stages of the disease, performance of objective 270 
response by RECIST was disappointing in capturing benefits of sorafenib therapy [3]. As a 271 
consequence of these failures, two strategies emerged: a) assess response according to the 272 
‘hallmarks of HCC’ for defining viable tumors (mRECIST criteria) [5,8], b) endorse TTP as a 273 
more adequate surrogate end-point, as per the SHARP trial results [5]. 274 
The present study defines objective response as an independent prognostic factor for OS, 275 
and as a potentially reliable surrogate end-point. First, we established an 11.5% ORR by 276 
mRECIST in patients treated with brivanib in the setting of BRISK-PS trial. This figure 277 
compares well with data from a phase III trial of brivanib in front-line advanced HCC, where 278 
an ORR of 12% in those 577 patients randomized to brivanib arm was reported [21]. 279 
Furthermore, in this study, ORR for sorafenib was 9%, which is within the range of 9–28% 280 
described in several retrospective studies [14–17,22,23]. These figures for sorafenib are far 281 
from the 2% ORR described for RECIST [5]. Thus, assessment of mRECIST in patients with 282 
advanced HCC treated with anti-angiogenic drugs, might be in line with other alternative 283 
criteria developed to measure response in other solid tumors. This is the case for Choi 284 
criteria, for the measurement of response in gastrointestinal stromal tumors treated 285 
with imatinib [24] or immune-related response criteria for melanomas treated with checkpoint 286 
inhibitors [25]. 287 
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Second, we sought to define if objective response was an independent predictor of OS in 288 
advanced HCC. For this purpose, we performed a multivariate time-dependent analysis that 289 
defined several variables related to tumoral status (macrovascular invasion, metastases, 290 
AFP >200 ng/ml), liver function (bilirubin, albumin) and treatment response measured by 291 
mRECIST as independent predictors for survival. This result is critical, since it represents 292 
the first requirement to propose ORR as surrogate end-point for OS in advanced HCC. In 293 
addition, the level of evidence is high due to the phase III randomized controlled nature of 294 
the original study. 295 
Finally, we aimed to explore if ORR could be used as a potential surrogate end-point in 296 
HCC. The way to evaluate therapeutic effectiveness in oncology is based upon a statistically 297 
significant and clinically meaningful improvement in OS [26]. In clinical research, surrogate 298 
end-points are used in order to provide earlier measures of difference in treatment effect 299 
than OS [1,27]. In our study, we identified a significant correlation between ORR assessed 300 
by mRECIST after brivanib and OS (R = −0.92). Notably, most patients with objective 301 
response could be identified in the first radiological evaluation conducted at 6 weeks. 302 
Moreover, objective response overcomes a limitation of other end-points that include 303 
disease stabilization in their definitions (disease control rate, TTP or progression-free 304 
survival [PFS]) since these end-points may be influenced by the inherent speed of 305 
progression of tumors independently of the effect of the drug [28]. This makes objective 306 
response by mRECIST a promising surrogate end-point to evaluate efficacy (if a treatment is 307 
effective for a certain condition) after a phase II trial, and thus to decide its further 308 
development. 309 
Thus, if ORR is an independent predictor of survival and a potentially good surrogate of OS, 310 
we need to explain how the differences in ORR between brivanib and placebo arms (Odds 311 
ratio 5.72; 95% CI, 1.41–23.25, p = 0.003) were unable to correlate with the lack of survival 312 
differences in this trial. The most obvious explanation is that the magnitude of the benefit 313 
obtained by a drug certainly depends on the type of ORR benefit (CR vs. PR) and the 314 
 14 
 
toxicity. The ORR obtained in the trial according to intention to treat for the brivanib arm was 315 
9.9% (26/263), a figure that is suboptimal to impact on the final OS result. Other effective 316 
drugs in cancer such as crizotinib, which achieved a 29% absolute increase in ORR 317 
compared to chemotherapy (74% vs. 45%) in non-small cell lung cancer [29], or nivolumab, 318 
which achieved 40% ORR in melanoma patients, but with a high rate of complete 319 
responses [30], are examples defining a threshold for ORR to directly impact in OS benefit. 320 
Therefore, to reliably predict differences among treatments, a higher magnitude of the 321 
difference in terms of quantity (percentage of objective response) and quality (presence of 322 
CRs or long-lasting responses) would be necessary. This concept is particularly challenging 323 
in the HCC field since, unlike other tumors, the post-progression time is generally longer 324 
than TTP and may dilute part of the benefit produced by the drug during treatment [18,31]. 325 
The importance of objective response as a surrogate end-point in cancer trials has been 326 
acknowledged in some papers by regulatory agencies and used in breakthrough trials [32]. 327 
Indeed, 24 of the 25 FDA accelerated marketing approvals for oncologic indications between 328 
2009 and 2014 were based on ORR [33]. This point is of significance since the last 329 
randomized studies conducted in HCC have shown inconsistencies between TTP and 330 
OS [34]. In this sense, for instance, the two positive trials showed similar OS rates for 331 
sorafenib in front-line and regorafenib in second line but with clearly distinct TTP 332 
figures [3,35]. Thus, TTP is currently re-visited as a surrogate end-point in trial design for 333 
advanced HCC. In order to provide absolutely robust data to enforce recommendations in 334 
guidelines, the definitive evidence will be obtained when several randomized trials following 335 
mRECIST assessment will be available, allowing this a meta-analysis approach comparing 336 
the Pearson correlation coefficient of ORR, TTP or other surrogate end-points with OS [36–337 
40]. 338 
In conclusion, these results provide high-level evidence, suggesting that radiological 339 
response in advanced HCC by mRECIST captures clinically meaningful outcomes in terms 340 
of OS and therefore, if confirmed in other future studies at individual and trial-level [36–40], 341 
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objective response can be proposed as a complementary surrogate end-point for the 342 
efficient development of clinical trials.  343 
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Table 1. Univariate and multivariate time-dependent analysis of OS in BRISK-PS 
patients who could be assessed for tumor response.  
Univariate analysis Multivariate analysis 
HR [95% CI] P value HR [95% CI] P value 
Distant metastasis 1.27 [0.96 - 1.67] 0.094 1.37 [1.05 - 1.78] 0.019 
Macrovascular invasion 1.77 [1.33 - 2.34] < 0.001 1.54 [1.19 - 1.99] 0.001 
Nodal metastasis 1.52 [1.17 - 1.99] 0.002 1.36 [1.07 - 1.73] 0.013 
AFP > 200ng/ml 2.02 [1.55 - 2.62] < 0.001 1.99 [1.56 - 2.54] < 0.001 
Albumin > median1 0.58 [0.45 - 0.75] < 0.001 0.65 [0.51 - 0.83] 0.001 
Bilirubin > median2 2.32 [1.78 - 3.03] < 0.001 2.24 [1.73 - 2.89] < 0.001 
OR mRECIST 0.28 [0.14 - 0.54] < 0.001 0.48 [0.26 - 0.91] 0.025 
 
1
 3.59g/dl, 
2
 0.98mg/dl. OR: Objective response.  
Variables with p value > 0.10 in univariate analysis were reason for sorafenib discontinuation, ECOG PS score, 
region, age, sex, race and risk factors. 
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Table 2. Univariate and multivariate time-dependent analysis of OS in patients treated 
with brivanib and who could be assessed for tumor response in BRISK-PS.  
Univariate analysis Multivariate analysis 
HR [95% CI] P value HR [95% CI] P value 
Distant metastasis 1.51 [1.06 - 2.16] 0.022 1.35 [0.97 - 1.89] 0.076 
Macrovascular invasion 1.85 [1.33 - 2.57] < 0.001 1.64 [1.20 - 2.24] 0.002 
Nodal metastasis 1.60 [1.16 - 2.22] 0.005 1.30 [0.96 - 1.77] 0.086 
AFP > 200ng/ml 2.16 [1.56 - 2.99] < 0.001 1.97 [1.44 - 2.69] < 0.001 
Albumin > median1 0.56 [0.41 - 0.77] < 0.001 0.58 [0.43 - 0.80] 0.001 
Bilirubin > median2 2.57 [1.85 - 3.57] < 0.001 2.31 [1.68 - 3.18] < 0.001 
OR mRECIST 0.31 [0.16 - 0.60] < 0.001 0.50 [0.25 - 0.99] 0.047 
1
 3.59g/dl, 
2
 0.98mg/dl. OR: Objective response. 
Variables with p value > 0.10 in univariate analysis were reason for sorafenib discontinuation, ECOG PS score, 
region, age, sex, race and risk factors. 
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Table 3. Baseline demographics and disease characteristics in patients with and 
without objective response by mRECIST after treatment with brivanib.  
 
OR: Objective response. *54 patients with more than one risk factor were excluded. (%). [range]. 
 
 OR (n=26) No OR (n=200) P value 
Age (median), years 63 [36–76] 63 [19–85] 0.933 
Sex 
   
Male 23 (88.5) 165 (82.5) 0.583 
Female 3 (11.5) 35 (17.5) 
 
Race 
   
White 13 (50.0) 84 (42.0) 0.530 
Asian 11 (42.3) 103 (51.5) 0.380 
Black/Afrincan American 0 (0) 10 (5.0) 0.380 
Other 2 (7.7) 3 (1.5) 0.100 
Region 
   
America & Europe 16 (61.5) 110 (55.0) 0.675 
Asia  10 (38.5) 90 (45.0) 
 
Risk factors* 
   
Alcoholic liver disease 6 (23.1) 20 (10.0) 0.093 
Hepatitis B 7 (26.9) 80 (40.0) 0.284 
Hepatitis C 7 (26.9) 43 (21.5) 0.615 
Other 2 (7.7) 7 (3.5) 0.277 
Child-Pugh class 
   
A 26 (100) 189 (94.5) 0.620 
B 0 (0) 11 (5.5) 
 
ECOG PS score 
   
0 21 (80.8) 125 (62.5) 0.082 
1/2 5 (19.2) 75 (37.5) 
 
Reason for sorafenib discontinuation 
   
Progression 21 (80.8) 177 (88.5) 0.337 
Intolerance 5 (19.2) 23 (11.5) 
 
BCLC stage 
   
A/B 9 (34.6) 18 (9.0) 0.001 
C 17 (65.4) 182 (91.0) 
 
Distant metastasis 9 (34.6) 142 (71.0) 0.001 
Nodal metastasis 7 (26.9) 76 (38.1) 0.387 
Macrovascular invasion 8 (30.8) 61 (30.5) 1.000 
AFP (median), ng/ml 24 [2–9101] 353 [1–1.2x106] 0.001 
Albumin (median), g/dl 4.0 [3.0–4.4] 3.5 [2.1–5.0] 0.002 
Bilirubin (median), mg/dl  0.9 [0.4–5.7] 0.98 [0.2 – 15.2] 0.191 
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Figure legends 
Fig. 1. Response assessment in HCC by mRECIST following the AASLD JNCI 
Guidelines (adapted from ref 8). CR: Complete response. PR: Partial response. SD: 
Stable disease. PD: Progressive disease. IR: Incomplete response. 
Fig. 2. Landmark Kaplan-Meier curve of OS between patients with response or not by 
mRECIST in BRISK-PS (A) and in those treated with brivanib (B). P value according to 
Mantel-Byar test. 
Fig. 3. Correlation between raw survival probability using deciles and odds of ORR in 
brivanib patients within BRISK-PS. Each one of the ten subgroups sorted by worse to 
better outcome has an observed ORR. The central regression line is their association. 
Internal and external 95% CI bands identify the uncertainty for expected value of the 
dependent variable and for the individual predicted value, respectively. 
Deciles of Survival Probability=-1.293-2.261*logOdds(ORR). 
Fig. 4. Correlation between HR for OS and odds ratio for ORR in five random 
subsamples of patients within BRISK-PS. The central regression line is their association. 
Internal and external 95% CI bands identify the uncertainty for expected value of the 
dependent variable and for the individual predicted value, respectively. 
ln(HR for OS)=0.621 -1.139*ln(Odds Ratio for ORR). 
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Fig. 1 
 
 
 
 
 
 
 
 
 
 
Measurable lesions Non measurable lesions 
Target lesions Non-target lesions 
Maximum of 2 per 
organ and 5 in total 
CR: Disappearance of any enhancement in all 
target lesions. 
   
PR: ≥30% decrease in the sum of diameters of 
viable (enhancement) target lesions, taking as 
reference the baseline sum of the diameters of 
target lesions. 
SD: Any cases that do not qualify for either PR or 
PD. 
PD: ≥20% increase in the sum of viable 
(enhancement) target lesions, taking as reference 
the smallest sum of viable (enhancement) target 
lesions recorded since treatment started. 
CR: Disappearance of any enhancement in all 
non-target lesions. 
   
SD/IR: Persistence of enhancement in one or 
more non-target lesions. 
PD: Appearance of one or more new lesions 
(typical lesions >1cm, atypical or extrahepatic 
lesions >1cm interval growth) and/or unequivocal 
progression of existing non-target lesions. 
*Pleural effusion or ascites requires 
cytopathological confirmation of the neoplastic 
nature when target lesions has met criteria for CR, 
PR or SD. 
Typical (enhancing) lesions: mRECIST  
Atypical (non-enhancing) lesions or  extrahepatic lesions: RECIST 
≥1cm lesions  
Short axis >2cm in porta hepatis lymph nodes 
<1cm or truly nonmesurable lesions 
Infiltrative type HCC, portal vein thrombosis 
Overall response 
CR: CR of target and non-target lesions. 
PR: CR of target and SD/IR of non-target lesions / PR of target and non-PD of non-target lesions. 
SD: SD of target lesions and non-PD of non-target lesions (including absence of new lesions). 
PD: PD of target or non-target lesions (including emergence of new lesions). 
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Fig. 2 
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Fig. 3 
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Fig. 4  
 
